Barcelona – Pittsburgh
Aquesta conferència s’ha convertit en una referència en el camp de la demència. Al maig de 2026, BcnPit tornarà a sorgir com un valuós fòrum on professionals de tot el món poden connectar-se i compartir el seu treball i perspectives sobre la demència.
Aquesta conferència d’alta qualitat reunirà panelistes de reconegut prestigi científic internacional i crearà un espai interactiu amb l’objectiu final d’ajudar a les persones afectades i a les seves famílies.
Ens veiem a Barcelona-Pittsburgh 2026!
PRESENCIAL BARCELONA-PITTSBURGH
Participa presencialment en aquesta trobada internacional exclusiva, connecta directament amb experts i viu una experiència única entre Barcelona i Pittsburgh.
BARCELONA-PITTSBURGH ONLINE
Segueix l’esdeveniment des d’on vulguis amb accés virtual. Gaudeix de ponències en directe, sessions interactives per avançar en el teu desenvolupament professional sense moure’t de casa.
Descobreix els ponents del BcnPit 2026
Professor of Neurology at the National and Kapodistrian University of Athens, with academic affiliation at Columbia University. His research focuses on cognitive reserve and lifestyle factors, including diet, in Alzheimer’s disease and aging.
Prof. Nikolaos Scarmeas, MD, PhD Professor of Neurology, National and Kapodistrian University of AthensClifford R. Jack Jr., M.D. is Professor of Radiology (Neuroradiology) and the Alexander Family Professor of Alzheimer’s Disease Research at Mayo Clinic in Rochester MN.
Prof. Clifford R. Jack, Jr., MD. Professor of Radiology and Alzheimer’s Disease Research, Mayo ClinicNeuropsychologist specializing in neurodegenerative dementias and acquired brain injury.
Prof. James Becker Chief Executive Officer, Brite Wellness, Inc.Distinguished Professor of Neurology and Neuroscience at the University of Yaoundé I, he is a leading figure in clinical and research leadership in Africa. Founder of the Brain Research Africa Initiative (BRAIN), his work focuses on neurodegeneration, epilepsy, and translational neuroscience. With over 230 publications, his contributions include advances in onchocerciasis-associated epilepsy and the development of the Actigraphic Sleep Score.
Alfred Njamnshi MD, MA, DMS, FMH Professor of Neurology and Neuroscience, FMBS, University of Yaoundé I, CameroonDr. Wepnyu Yembe Njamnshi is a physician–scientist specializing in neuropsychology and brain health in Africa, and Director of Operations at Brain Research Africa Initiative (BRAIN). He leads major initiatives in dementia research, including the BUILD-FSA programme and the Cameroon National Dementia Plan Project. His work focuses on strengthening research capacity and advancing innovative solutions across the continent.
Yembe Njamnshi, MD, MSc Director of Operations, Brain Research Africa Initiative (BRAIN); Research Executive, Ministry of Public Health (Cameroon)Associate Professor of Bioinformatics at the Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, within the Department of Biochemistry and Structural Biology at UT Health San Antonio, USA.
He also serves as Program Director of the African Initiative for Bioinformatics Online Training in Neurodegenerative Diseases (AI-BOND).
His research focuses on the intersection of artificial intelligence and healthcare, developing advanced methods in biomedical machine vision, multimodal learning, and generalist AI to support clinical decision-making.
He is a Senior Member of IEEE and Fellow of the American Heart Association, with work funded by major institutions including NIH and Gates Ventures
Laia Montoliu-Gaya, PhD, Assistant Professor at University of Gothenburg
Laia Montoliu, PhD Assistant Professor at University of GothenburgDirector of the Multiple Sclerosis Center of Catalonia (Cemcat) at Vall d’Hebron University Hospital and Head of the Neuroimmunology Research Group at the Vall d’Hebron Research Institute.
Xavier Montalbán, MD, PhD Director of the Multiple Sclerosis Center of Catalonia (Cemcat) and Head of Neuroimmunology Research, Vall d’HebronAt Ace, he design CTs and other global CT from pharmaceutical companies, participate in international boards to improve CT management and promote research projects to validate novel biomarkers for an early detection of the disease and find novel therapeutical approaches.
Xavier Morató, PhD Pharmacy Unit at AceBruno Vellas is a leading expert in geriatrics and healthy aging, founder of major international initiatives such as EADC, CTAD, and ICFSR.
Prof. Bruno Vellas, MD, PhD Professor of Medicine and President Founder of IHU HealthAge, Toulouse University HospitalProf. Michael T. Heneka is a neurologist and clinician-scientist with over 25 years of experience in neurodegenerative diseases. His research focuses on neuroinflammation and immune mechanisms in disorders such as Alzheimer’s and Parkinson’s disease.
Prof. Michael Heneka, MD, PhD Professor of Neurology and NeuroimmunologyHe has more than 20 years of experience in basic, clinical and applied research in drug dependence, psychopathology and memory disorders.
Sergi Valero, PhD Head of Medical Psychology at Ace Alzheimer Center BarcelonaDr. Villemagne is a physician–scientist and Tenured Professor specializing in the development of molecular biomarkers for the discovery, diagnosis, prognosis, and clinical trials of neurodegenerative diseases.
Prof. Victor L Villemagne, MD Tenured Professor and Co-Director of Molecular Biomarkers in Psychiatry at the University of PittsburghDr. Cano is in charge of the molecular biology unit of Ace Alzheimer Center Barcelona and her studies are related to the clinical evaluation of early biomarkers of Alzheimer’s disease.
Amanda Cano, PhD Postdoctoral Researcher at AceThe main objective of his genomic research group is to understand the causes of Alzheimer’s disease and other dementias by integrating genetic, transcriptomic and proteomic data.
Agustín Ruiz, MD, PhD Director of Research at Ace Alzheimer Center BarcelonaDr. Boada focuses her research on the treatment of AD and related dementias, especially on the genotype and phenotype of common degenerative diseases and the design of new pharmacological and non-pharmacological treatments.
Prof. Mercè Boada, MD, PhD Chief Medical Officer and founding member of Ace Alzheimer Center BarcelonaZONA DE PONENTS
PROGRAMA DEL BCNPIT 2026




































































